Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BY101298 in advanced solid tumors
NCT06462716Phase 1Active, not recruiting
- Sponsor
- Baiyu Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BY101298 in malignant solid tumor, sponsored by Baiyu Pharmaceutical. Primary endpoints: Safety and tolerability of BY101298 and Maximum Tolerated Dose. Started Apr 2023; status: active, not recruiting.
02
Drugs
BY101298
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06462716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462716.